Nuvonis Technologies GmbH

Nuvonis is a biotech company based in Vienna, Austria, providing innovative cell banks and technical support for vaccine development. The Nuvonis team is highly experienced in all aspects of vaccine production, both in small biotech companies up to major international pharmaceutical companies. Based on our experience, Nuvonis offers solutions that reduce development timelines, ensure optimal quality and prevent risks in your product development. The fully characterised Nuvonis Vero cells (GMP) are cultivated without animal-derived media or protease additives and are non-tumorigenic beyond the end of production passage. We are offering proprietary and efficient virus purification processes for the generation of high-purity vaccine bulk drug substance with low host cell DNA and protein impurities. Nuvonis has developed a novel continuous avian cell line (CCX) from primary quail (Coturnix japonica). Nuvonis avian cell banks are available both for adherent growth and growth in suspension. Nuvonis provides “ready to use” GMP Master and GMP Working Cell Banks.